3dprintingindustry.com
L'Oreal will develop and approve the finance. If created in the laboratory human tissue satisfy the customer, the Organovo will get exclusive rights to the product.
L'Oreal Group owns 30 beauty-known brands around the world, including Garnier, Kiehl's, Lancome, L'Oreal Paris, Maybelline New York, Urban Decay and Redken. In 1989, the company stopped testing their products on animals, began to develop alternative methods. Since that time, all tests are carried out on an artificial skin tissue culture Episkin.
Organovo is developing a live human tissue, using its own technology for 3D-biopechati. Even human organs can grow the printed cells.
In April. the company announced the Creation of 3D-printed fabric exVive3D Liver, which can be used to assess renal toxicity in humans. After this statement, Organovo signed a major multi-year contract with the pharmaceutical giant Merck & Co, which is interested in using the the bioprint technology technology NovoGen exVive3D Liver and models for the development of new drugs.
- Many people do not fully understand what is now under investigation. It is assumed not only the printing of non-human cells, but also the fusion of human cells with foreign cells. We believe that interest in this arise when people, depending on the level of their education, will begin to realize what opportunities open up in front of them, - reported in the Gartner.
Much of the research in the field of bioprint are conducted by universities and start-up companies. They are far from complete and should be approved by the governmentas itt should be aware of developments in this field.
Organovo, a start-up specializing in the development of 3-D bioprint technology, held an IPO three years ago and today has a staff of 65 people with a market capitalization of $ 500 million.
The project to develop materials for bioprint transplants for patients with skin lesions was launched in conjunction with the Faculty of Medicine at Yale University.
Research segment of personal care products is one of the leading destinations for Technologies 3D- bioprint, following from the findings of the research company IDTechEx, which gave a forecast of the segment until 2024.
In the November Organovo announced the commercial launch of human liver tissue exVive3D Human Liver Tissue for testing the toxicity and preclinical trials of new drugs.
The product reproduces liver tissue to the cellular level and is able to produce protein.
The tests of the product showed its 100% capacity to respond to toxic and non-toxic substances, in full compliance with the patterns laid down in the living tissue of the liver, which allows to obtain high-precision biochemical and histological data.
Thus, the joint research with L'Oreal have all chances to give the market the expected result.
source: ibtimes.co.uk
L'Oreal Group owns 30 beauty-known brands around the world, including Garnier, Kiehl's, Lancome, L'Oreal Paris, Maybelline New York, Urban Decay and Redken. In 1989, the company stopped testing their products on animals, began to develop alternative methods. Since that time, all tests are carried out on an artificial skin tissue culture Episkin.
Organovo is developing a live human tissue, using its own technology for 3D-biopechati. Even human organs can grow the printed cells.
In April. the company announced the Creation of 3D-printed fabric exVive3D Liver, which can be used to assess renal toxicity in humans. After this statement, Organovo signed a major multi-year contract with the pharmaceutical giant Merck & Co, which is interested in using the the bioprint technology technology NovoGen exVive3D Liver and models for the development of new drugs.
- Many people do not fully understand what is now under investigation. It is assumed not only the printing of non-human cells, but also the fusion of human cells with foreign cells. We believe that interest in this arise when people, depending on the level of their education, will begin to realize what opportunities open up in front of them, - reported in the Gartner.
Much of the research in the field of bioprint are conducted by universities and start-up companies. They are far from complete and should be approved by the governmentas itt should be aware of developments in this field.
Organovo, a start-up specializing in the development of 3-D bioprint technology, held an IPO three years ago and today has a staff of 65 people with a market capitalization of $ 500 million.
The project to develop materials for bioprint transplants for patients with skin lesions was launched in conjunction with the Faculty of Medicine at Yale University.
Research segment of personal care products is one of the leading destinations for Technologies 3D- bioprint, following from the findings of the research company IDTechEx, which gave a forecast of the segment until 2024.
In the November Organovo announced the commercial launch of human liver tissue exVive3D Human Liver Tissue for testing the toxicity and preclinical trials of new drugs.
The product reproduces liver tissue to the cellular level and is able to produce protein.
The tests of the product showed its 100% capacity to respond to toxic and non-toxic substances, in full compliance with the patterns laid down in the living tissue of the liver, which allows to obtain high-precision biochemical and histological data.
Thus, the joint research with L'Oreal have all chances to give the market the expected result.
source: ibtimes.co.uk
